These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15193996)

  • 1. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates.
    Schäfer SA; Hansen BC; Völkl A; Fahimi HD; Pill J
    Biochem Pharmacol; 2004 Jul; 68(2):239-51. PubMed ID: 15193996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys.
    Bodkin NL; Pill J; Meyer K; Hansen BC
    Horm Metab Res; 2003 Oct; 35(10):617-24. PubMed ID: 14605998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
    Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys.
    Hoivik DJ; Qualls CW; Mirabile RC; Cariello NF; Kimbrough CL; Colton HM; Anderson SP; Santostefano MJ; Morgan RJ; Dahl RR; Brown AR; Zhao Z; Mudd PN; Oliver WB; Brown HR; Miller RT
    Carcinogenesis; 2004 Sep; 25(9):1757-69. PubMed ID: 15131011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
    Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha.
    Kane CD; Francone OL; Stevens KA
    Gene; 2006 Oct; 380(2):84-94. PubMed ID: 16828988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643.
    Edvardsson U; Alexandersson M; Brockenhuus von Löwenhielm H; Nyström AC; Ljung B; Nilsson F; Dahllöf B
    Electrophoresis; 1999; 20(4-5):935-42. PubMed ID: 10344269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist.
    Aleo MD; Lundeen GR; Blackwell DK; Smith WM; Coleman GL; Stadnicki SW; Kluwe WM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1173-82. PubMed ID: 12626651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR agonists in the treatment of insulin resistance and associated arterial disease.
    Camejo G
    Int J Clin Pract Suppl; 2003 Mar; (134):36-44. PubMed ID: 12793596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
    Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
    J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
    Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
    J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPARalpha).
    Meyer K; Völkl A; Endele R; Kühnle HF; Pill J
    Arch Toxicol; 1999 Nov; 73(8-9):440-50. PubMed ID: 10650915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
    Vikramadithyan RK; Hiriyan J; Suresh J; Gershome C; Babu RK; Misra P; Rajagopalan R; Chakrabarti R
    Obes Res; 2003 Feb; 11(2):292-303. PubMed ID: 12582227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in liver PPARalpha mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice.
    Hsu SC; Huang CJ
    J Nutr Biochem; 2007 Feb; 18(2):86-96. PubMed ID: 16713235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
    Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K
    Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.
    Yeon JE; Choi KM; Baik SH; Kim KO; Lim HJ; Park KH; Kim JY; Park JJ; Kim JS; Bak YT; Byun KS; Lee CH
    J Gastroenterol Hepatol; 2004 Jul; 19(7):799-804. PubMed ID: 15209628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
    Kuwabara K; Murakami K; Todo M; Aoki T; Asaki T; Murai M; Yano J
    J Pharmacol Exp Ther; 2004 Jun; 309(3):970-7. PubMed ID: 14982965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
    Ide T; Tsunoda M; Mochizuki T; Murakami K
    Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
    Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
    Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.